We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Levels of Key Protein Linked to Pancreatic Cancer Risk

By HospiMedica staff writers
Posted on 30 Aug 2007
People with lower blood levels of a protein called insulin-like growth factor-binding protein (1IGFBP-1) are more likely to develop pancreatic cancer than those with higher levels. More...


The risk may be elevated because higher amounts of IGFBP-1 are able to soak up more IGF, leaving less available to spur pancreatic cancer cell growth, or because IGFBP-1 has some cancer-blocking properties of its own. Another possibility is that other molecules may be involved, for which IGFBP-1 acts as an intermediary. Further work is required to determine whether 1IGFBP-1 is a reliable indicator of pancreatic cancer risk.

In a large study, investigators measured circulating IGFBP-1 levels in a select group of participants in four large, ongoing health studies: the Health Professionals Follow-up Study, the Nurses' Health Study, the Physicians' Health Study, and the Women's Health Initiative. They collected blood samples from 573 participants and, four or more years later, checked IGFBP-1 levels in the samples of 144 people who developed pancreatic cancer and 429 who did not.

They found that the quarter of the group whose IGFBP-1 levels were lowest had twice the risk of developing pancreatic cancer of those in the top three-quarters. The connection became even stronger over time--among cases diagnosed at least eight years after blood collection, those in the bottom quarter of IGFBP-1 levels had nearly three-and-a-half times the pancreatic cancer risk of those in the upper quarter. A report of the study appeared in the August 15, 2007, issue of the journal Cancer Research.

The levels of insulin and another circulating hormone, insulin-like growth factor or IGF, are modified by obesity and sedentary lifestyle, and there is evidence that these hormones may stimulate the growth of pancreatic cancer cells, said the study's lead author, Brian Wolpin, M.D, from Dana-Farber Cancer Institute (Boston, MA, USA). When IGF binds to proteins like IGFBP-1, there may be less IGF available to bind to pancreatic cancer cells and promote their growth. We wanted to determine whether IGFBP-1 levels in the blood were associated with pancreatic cancer risk.


Related Links:
Dana-Farber Institute

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Wound Irrigation Solution
Prontosan®
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.